Methods for promoting myelination and for treating demyelinating diseases
AssigneeThe Scripps Research Institute
InventorsLuke Lairson, Brittney Beyer, Mingliang Fang, Gary Siuzdak
Life of this patent
Estimating the term…
Loading patent…
AssigneeThe Scripps Research Institute
InventorsLuke Lairson, Brittney Beyer, Mingliang Fang, Gary Siuzdak
Estimating the term…
This invention provides novel methods for treating or ameliorating symptoms of demyelinating diseases such as multiple sclerosis. The methods involve administering to subjects in need of treatment a pharmaceutical composition that contains a therapeutically effective amount of taurine and also a compound that induces oligodendrocyte precursor cell (OPC) differentiation (e.g., T3, benztropine, clemastine or miconazole). Some of the methods additionally involve administration to the subject a known agent for treating demyelinating diseases (e.g., SIP receptor agonists) or a known disease modifying drug. The invention also provides methods for increasing myelination and methods for promoting OPC differentiation into oligodendrocytes. These methods entail contacting a population of OPCs with a combination of taurine and a known OPC differentiation-inducing agent such as T3, clemastine, benztropine or miconazole.
A method for treating or ameliorating one or more symptoms of a demyelinating disease in a subject, comprising administering to the subject (a) a pharmaceutical composition comprising a therapeutically effective amount of taurine or a taurine-like compound and (b) an agent that induces oligodendrocyte precursor cell (OPC) differentiation, thereby treating or ameliorating the symptoms of the demyelinating disease in the subject.
A method for increasing myelination in a subject, comprising administering to the subject (a) a pharmaceutical composition comprising a therapeutically effective amount of taurine or a taurine-like compound, and (b) an agent that induces OPC differentiation.
A pharmaceutical composition, comprising (a) a therapeutically effective amount of taurine or a taurine-like compound and (b) one or more agents that induce OPC differentiation or treat a demyelinating disease.
Dependencies are inferred from the claim text.